MedPath

Treatment of iron overload in thalassemia patients

Phase 2
Conditions
Thalassemia.
Beta thalassaemia
Registration Number
IRCT2016041627412N1
Lead Sponsor
Vice Chancellor for research of Urmia University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
36
Inclusion Criteria

Inclusion Criteria: Transfusion-dependent Thalassemia; Age more than three years; Serum ferritin level > 5,000 ng/L and progressively increasing undergoing chelating therapy with subcutaneous DFO

Exclusion Criteria

Severe liver, kidney or cardiac disease; Serious adverse events with DFO or DFP; Neutriphil count < 2000/L during the past 2 years; Platelet count < 100,000/L; History of arthropathy

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum ferritin. Timepoint: before intervention and in 2, 4, 6, 8, 10 and 12 month intervals after intervention. Method of measurement: ng/mL.
Secondary Outcome Measures
NameTimeMethod
Complete blood count. Timepoint: before intervention and monthly for 12 month after intervention. Method of measurement: blood examination.
© Copyright 2025. All Rights Reserved by MedPath